AF
GLUE icon

Amalgamated Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Amalgamated Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$40K Buy
+2,832
New +$39.3K ﹤0.01% 2521

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Amalgamated Financial's GLUE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2022: 2,832 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #2521 among its holdings.

52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

  • Amalgamated Financial held 2,832 shares of Monte Rosa Therapeutics worth $40K as of Q1 2022.
  • Monte Rosa Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Monte Rosa Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2521 holding.
  • 52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.